Dr Rolfo talks with ecancer at the Best of ASCO 2017 meeting in Miami about new drug advancements that were presented at the ASCO annual meeting. He discusses the new NTRK inhibitor, larotrectinib, which is yielding a 76% response rate and a 12% complete...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uIrCAD
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
Objective Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation...
-
Abstract Objective To study the effects of Astragalus polysaccharide (APS), the primary effective component of the Chinese herb medicine A...
-
Geriatric trauma: A population-based study Saint Shiou-Sheng Chen, Li-Chien Chien Formosan Journal of Surgery 2019 52(2):39-44 Background: G...
-
Objectives Adult sagittal posture is established during childhood and adolescence. A flattened or hypercurved spine is associated with poore...
-
Related Articles Randomized clinical trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in patients wit...
-
Abstract Objective To evaluate Chinese medicine (CM) formula Bazheng Powder (八正散) as an alternative therapeutic option for female patients...
-
Related Articles Disrupted relationship between "resting state" connectivity and task-evoked activity during social percepti...
-
World Community; and Remarks on our Own Behalf Models of Anticipation Within the Responsible Research and Innovation Framework: the Two RRI ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου